SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hall A, Logan J, Toblin R, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:26132620.
  • 2
    Paulozzi L, Budnitz D, Yongli X. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15:618627.
  • 3
    Fingerhut LA. Increases in methadone-related deaths: 1999-2004. National Center for Health Statistics. Available at: http://www2d.cdc.gov/ncidod/ts/print.asp. Accessed March 19, 2009.
  • 4
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Special data runs, Excel-All_sup_1created on April 23, 2009.
  • 5
    International Statistical Classification of Diseases and Related Health Problems 10th Revision, Version for 2007. Available at: http://apps.who.int/classifications/apps/icd/icd10online/. Accessed March 31, 2009.
  • 6
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Data Archive. Available at: http://www.icpsr.umich.edu/cocoon/SAMHDA/DAS3/00056.xml. Accessed April 29, 2009.
  • 7
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2003). Results from the 2002 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NHSDA Series H-22, DHHS Publication No. SMA 03–3836). Rockville, MD, Table 1.107 A & B.
  • 8
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2005). Overview of Findings from the 2004 National Survey on Drug Use and Health (Office of Applied Studies, NSDUH Series H-27, DHHS Publication No. SMA 05-4061). Rockville, MD, Tables 1.129 A and B.
  • 9
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2006). Results from the 2005 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-30, DHHS Publication No. SMA 06-4194). Rockville, MD, Table 1.28 A&B.
  • 10
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2009). Results from the 2008 National Survey on Drug Use and Health: National Findings (NSDUH Series H-36, DHHS Publication No. SMA 09-4343). Rockville, MD, Detailed tables 1.89 A&B.
  • 11
    SDI Vector data provided by Covidien, June 8, 2009.
  • 12
    RADARS, 2008 human exposure calls, data run April 10, 2009.
  • 13
    Texas Department of State Health Services, Texas Poison Center Network, special data run, April 3, 2009.
  • 14
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Special data runs, April 24, 2009.
  • 15
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Special data runs, May 5, 2009.
  • 16
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) Highlights—2007 National Admissions to Substance Abuse Treatment Services. OAS Series #S-45, HHS Publication No. (SMA) 09-4360, Rockville, MD, 2009.
  • 17
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS): 1993-2003. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-29, DHHS Publication No. (SMA) 05-4118, Rockville, MD, 2005.
  • 18
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. (2007). Treatment Episode Data Set (TEDS), 1992-2005. Concatenated data [Computer file]. Original data prepared by Synectics for Management Decisions, Incorporated. ICPSR ed. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [producer and distributor]. Data downloaded on April 15, 2008.
  • 19
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on Substance Abuse Treatment Facilities, DASIS Series: S-44, DHHS Publication No. (SMA) 08-4348, Rockville, MD, 2008.
  • 20
    Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. NCHS data brief, no 22. Hyattsville , MD : National Center for Health Statistics. 2009.
  • 21
    Warner M, Fingerhut L, Chen Li-H. Methadone deaths, 1999–2005, Findings from the National Vital Statistics System, National Center for Health Statistics, PowerPoint presentation dated November 2008.
  • 22
    RADARS System Poison Center Methadone Mortality Data, April 14, 2009.
  • 23
    Maxwell J. Poster, Increases in Methadone-Related Adverse Events. Is it pills or liquid? American Conference on Pain Medicine, New York City , April 2008.
  • 24
    U.S. Department of Justice, Drug Enforcement Administration, NFLIS 25 Most Frequently Identified Substances, data downloaded May 15, 2009.
  • 25
    U.S. Department of Justice, Drug Enforcement Administration, Special data runs, April 29, 2009 and May 9, 2009.
  • 26
    McNicholas L. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: A treatment improvement protocol (TIP 40). Rockville , MD : U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, 2004.
  • 27
    Jones H, Johnson R, Jasinski D, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: Effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:110.
  • 28
    Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;103:2529.
  • 29
    Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction. 2001;96:267272.
  • 30
    Sporer K. Buprenorphine: A primer for emergency physicians. Ann Emergency Med 2004;43:580584.
  • 31
    United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies . National Survey on Drug Use and Health, 2006 [Computer file]. ICPSR21240-v4. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2009-08-12. doi:10.3886/ICPSR21240.
  • 32
    Colliver J, Kroutil L, Dai L, et al. (2006). Misuse of prescription drugs: Data from the 2002, 2003, and 2004 National Surveys on Drug Use and Health (DHHS Publication No. SMA 06-4192, Analytic Series A-28). Rockville , MD : Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
  • 33
    Iguchi M, Handelsman L, Bickel W, et al. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 1993;32:257266.
  • 34
    Nielsen S, Dietz P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007;102:616622.
  • 35
    Thirion X, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practitioners in a French region. Drug and Alcohol Dependence. 2002;65:197204.
  • 36
    Lavie E, Fatséas M, Denis C, et al. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence. Drug Alcohol Depend. 2009;99:338344.
  • 37
    Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: Findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24:411418.
  • 38
    Peles E, Schreiber S, Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend. 2006;82:103110.
  • 39
    Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. Am J Addict. DOI: DOI: 10.1111/j.1521-0391.2009.00007.x.
  • 40
    Trescot A, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133S153.
  • 41
    Nutt D, Malizia A. New insights into the role of the GABAA–benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001;179:390396.
  • 42
    Preston K, Griffiths R, Cone E, et al. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend. 1986;18:192202.
  • 43
    Nielsen S, Dietze P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007;102:616622.
  • 44
    Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25:7985.
  • 45
    Flockhart D. (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed August 31, 2009.
  • 46
    Ferrari A, Coccia C, Bertolini A, et al. Methadone: Metabolism, pharmacokinetics, and interactions. Pharmacol Res 2004;50:551559.
  • 47
    Gerber J, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001;27:153160.
  • 48
    Flockhart D. (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed August 31, 2009.
  • 49
    Krantz M, Kutinsky I, Robertson A, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy. 2003;23:802805.
  • 50
    Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569580.
  • 51
    Flockhart D. (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed August 31, 2009.
  • 52
    Bornstein S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol. 2007;63:821827.
  • 53
    Waters B, Kaustubh G. Intravenous Quetiapine-Cocaine Use (“Q-Ball”). Am J Psychiatry. 2007;164:173174.
  • 54
    Uehlinger C, Crettol S, Chassot P, et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol. 2007;27:273278.
  • 55
    Physician's Desk Reference. (2007). Prescribing information: Zyprexa (olanzepine). 61:18301838.
  • 56
    Physician's Desk Reference. (2007). Prescribing information: Risperdal (risperidone). 61:16761682.
  • 57
    Vandel P, Talon JM, Haffen E, et al. Pharmacogenetics and drug therapy in psychiatry–the role of the CYP2D6 polymorphism. Curr Pharmaceutical Design 2007;13:241250.
  • 58
    Shah N, Lathrop S, Landen M. Unintentional methadone-related overdose death in New Mexico (USA) and implications for surveillance, 1998-2002. Addiction 2005;100:176188.
  • 59
    Graham N, Merlo L, Goldberger B, et al. Methadone- and heroin-related deaths in Florida. Am J Drug Alcohol Abuse. 2008;34:347353.
  • 60
    Sims S, Snow L, Porucznik C. Surveillance of methadone-related adverse drug events using multiple public health data sources. J Biomed Inform 2007;40:382289.
  • 61
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, (2007). Summary Report of the: Methadone Mortality Meeting—A Reassessment, Available at: http://dpt.samhsa.gov/pdf/Methadone_Report_10%2018%2007_Brief%20w%20attch.pdf. Accessed June 8, 2009.
  • 62
    FDA Amendments Act of 2007 (FDAAA).